GlaxoSmithKline Biologicals
On July 1, 2008, Innogenetics granted GlaxoSmithKline Biologicals a worldwide non-exclusive restricted license to use its proprietary SPF10 technology in clinical and epidemiological HPV vaccine studies. Innogenetics will receive royalties for each test performed during the studies.